Core Viewpoint - The sales of CAR-T cell therapy Carvykti (西达基奥仑赛) have significantly increased, but the stock price of Legend Biotech (传奇生物) has declined following the earnings report from Johnson & Johnson (强生) [1] Group 1: Financial Performance - Johnson & Johnson reported a total revenue of $94.193 billion for 2025, a year-on-year increase of 6% [1] - Carvykti generated $1.887 billion in revenue for 2025, representing a 95.95% increase compared to $963 million in 2024 [1] - In Q4 2025, Carvykti's sales reached $555 million, a 65.8% year-on-year increase, but only a 5.9% quarter-on-quarter growth [1] Group 2: Market Position and Product Development - Carvykti is positioned as a one-time therapy for relapsed or refractory multiple myeloma and has been approved in the U.S., EU, and Japan [3] - The product was priced at $465,000 per dose in the U.S., which is approximately three times the price of other domestic CAR-T products [3] - Legend Biotech aims to achieve profitability in 2026 by expanding Carvykti's application globally and increasing its use in community healthcare settings [4] Group 3: Production and Clinical Trials - Legend Biotech has completed the expansion of its production facility in Raritan, which is the largest CAR-T production base in the U.S., capable of supporting the treatment of up to 10,000 patients annually [4] - The company has initiated a Phase 3 clinical trial (CARTITUDE-6) for new indications targeting newly diagnosed multiple myeloma patients [4] Group 4: Market Challenges and Pricing - The commercialization of Carvykti in China lagged behind the U.S. market by two years, with approval granted in August 2024 [7] - The pricing strategy for the Chinese market has not yet been disclosed, and the product has not participated in national health insurance negotiations [7] - The high costs associated with CAR-T therapies pose challenges for accessibility, despite ongoing efforts to explore diverse payment models [8][9]

Core Insights - The article discusses the challenges and developments surrounding CAR-T cell therapy in China, particularly its high costs and recent inclusion in the commercial insurance innovation drug directory, which aims to improve accessibility for patients [4][16]. Group 1: CAR-T Therapy Overview - CAR-T therapy is a personalized immunotherapy that modifies a patient's T cells to target cancer cells, but it is associated with high costs, making it inaccessible for many patients [2][3]. - In the U.S., CAR-T therapy costs between $370,000 and $500,000, while in China, domestic CAR-T products range from 999,000 to 1,290,000 RMB [3][12]. Group 2: Insurance and Accessibility - The newly established commercial insurance innovation drug directory includes five domestic CAR-T therapies, which were previously excluded from the national basic medical insurance directory due to high costs [4][5]. - The directory aims to provide more treatment options for patients and reduce their financial burden, allowing for a multi-tiered payment system [5][16]. Group 3: Patient Experiences - Many patients face significant financial challenges when considering CAR-T therapy, often relying on commercial insurance or regional health insurance to cover part of the costs [8][9]. - The experiences of patients highlight the disparity in financial burdens, with some families still needing to pay substantial out-of-pocket expenses despite insurance coverage [10][11]. Group 4: Market Dynamics and Future Prospects - The commercial insurance innovation drug directory is seen as a milestone for CAR-T therapies, potentially leading to increased market access and improved patient outcomes [16][21]. - Companies are exploring various pricing and payment models to balance affordability for patients while ensuring profitability [12][14]. - The directory's implementation is expected to enhance collaboration between pharmaceutical companies and insurance providers, facilitating better access to innovative therapies [19][22].